Pulse Biosciences, Inc. — Q1 2024 Form 10-Q
Business context and reporting period. The filing covers the three months ended March 31, 2024. Pulse develops Nano-pulse Stimulation (NPS), also called nanosecond pulsed-field ablation (nsPFA), medical technology. Its primary focus is developing CellFX-based products for atrial fibrillation and selected other applications. The company had ceased dermatology sales and marketing and reported no product revenue in either comparable quarter.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $6.741 million | $5.829 million; up $0.912 million |
| General and administrative expense | $3.874 million | $3.733 million; up $0.141 million |
| Total operating expenses | $10.615 million | $9.562 million; up $1.053 million |
| Net loss | $10.137 million | $9.801 million; loss increased $0.336 million |
| Net loss per share, basic and diluted | $0.18 | $0.26 |
| Cash used in operating activities | $9.780 million | $6.570 million |
| Cash and cash equivalents at period-end | $34.885 million | $44.365 million at Dec. 31, 2023 |
| Total assets / total liabilities | $49.164 million / $12.877 million | $59.154 million / $14.794 million at Dec. 31, 2023 |
| Lease liabilities | $8.897 million | $9.144 million at Dec. 31, 2023 |
Gross margin and operating margin are not meaningful because the company had no revenue. The filing reports no borrowings outstanding under the former related-party loan, which was extinguished in May 2023; lease liabilities remain. Net interest income was $0.478 million, compared with net interest expense of $0.239 million in Q1 2023. The filing does not provide a clear cash runway beyond management’s estimate below.
Material changes and operating developments
- Operating cash use increased by $3.210 million year over year. Management attributed Q1 2024 operating cash use principally to the net loss, noncash stock compensation and depreciation/amortization, and a decline in accrued expenses.
- R&D expense rose primarily with higher stock-based compensation, employee-related costs and paid services. Total stock-based compensation increased to $1.759 million from $0.896 million.
- In March 2024, the FDA granted 510(k) clearance for the CellFX nsPFA Percutaneous Electrode System for soft-tissue ablation in percutaneous and intraoperative surgical procedures.
- The company initiated a cardiac catheter clinical study in Prague in December 2023 and described early acute and remapping data as promising. It filed a 510(k) application for its cardiac clamp in January 2024; following FDA feedback, it is assessing additional data requirements and says U.S. human clinical data are presently expected to be required. No regulatory timeline was provided.
- The thyroid-nodule first-in-human study in Italy was expanded to optimize treatment parameters; the company expects to complete it, including follow-up, in 2025.
Liquidity, outlook and risks
Management says current resources are expected to fund operations into the first quarter of 2025 under its operating plan, but not for 12 months from issuance of the financial statements. The company therefore disclosed substantial doubt about its ability to continue as a going concern and expects continued losses for several years unless it can generate substantial product revenue and reach profitability.
The principal financing plan is a proposed rights offering expected to close in Q2 2024, subject to completion and market conditions. Subsequent-event disclosure describes an offering of up to $60 million of units, with the subscription price expected to be the lesser of $10 per unit or the specified 10-trading-day volume-weighted average price. Each unit is expected to include one common share and two warrants, each covering one-half share. The rights are expected to be non-transferable; the offering terms and proceeds were not yet final, and there was no assurance of full subscription or financing on acceptable terms. The company also cited potential equity or debt financing and collaborations. Additional equity could dilute shareholders.
- Product and regulatory risk: Cardiac products remain in development; clinical outcomes, FDA requirements, approval timing and physician adoption are uncertain. The cardiac catheter is expected to require the FDA PMA pathway in the U.S.
- Funding and execution risk: Without timely capital, the company may reduce staffing, development, trials or other operations, or pursue licensing or other alternatives.
- Other risks: Competition from larger device companies, reimbursement uncertainty, reliance on third-party suppliers, intellectual-property and product-liability exposure, and volatility in capital markets. The company identifies Robert W. Duggan as beneficial owner of approximately 69% of outstanding common stock, creating control, liquidity and related-party considerations.
- Contingency: A former CFO’s arbitration seeks severance and other remedies. The company disputes the claims, says it cannot estimate a possible loss, and has not accrued a liability because it does not consider one probable.
Important facts for investors to verify
- Whether the proposed rights offering closed, the final terms and proceeds, participation levels, and resulting dilution.
- Actual cash use and runway relative to management’s estimate that funds extend into Q1 2025.
- Clinical-study progress and final data for the cardiac catheter and thyroid study, and FDA requirements and timing for the cardiac clamp.
- Whether the newly cleared percutaneous electrode is installed and adopted by hospitals and clinics, and whether it generates revenue.
- Changes in operating expenses, stock-based compensation, and related-party or governance matters involving the controlling shareholder.